8-K: CG Oncology Stockholders Elect Directors and Ratify Auditor at 2025 Annual Meeting

CG Oncology, Inc. announced the successful election of three Class I directors and the ratification of Ernst & Young LLP as its independent auditor at its 2025 Annual Meeting of Stockholders.

Summary

• CG Oncology, Inc. held its 2025 Annual Meeting of Stockholders on June 5, 2025.
• As of the record date, April 8, 2025, 76,221,857 shares of common stock were outstanding and entitled to vote.
• Stockholders elected three Class I directors: Arthur Kuan, James J. Mul, and Leonard Post, each to serve until the 2028 Annual Meeting of Stockholders.
• Arthur Kuan received 57,636,262.53 votes For and 3,625,893.00 votes Withhold.
• James J. Mul received 34,062,064.00 votes For and 27,200,091.53 votes Withhold.
• Leonard Post received 52,459,292.00 votes For and 8,802,863.53 votes Withhold.
• Stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, with 69,688,802.00 votes For, 7,027.00 votes Against, and 14,335.00 Abstentions.

Sentiment

Score: 7

Explanation: The filing reports the routine successful completion of the annual stockholder meeting, including the election of directors and ratification of the independent auditor. However, one director received a notable percentage of 'withhold' votes, indicating some shareholder dissent, which slightly tempers the overall positive sentiment.

Positives

• All three proposed Class I directors, Arthur Kuan, James J. Mul, and Leonard Post, were successfully elected to the Board.
• The selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was overwhelmingly ratified by stockholders.

Negatives

• Director James J. Mul received a significant number of 'Withhold' votes (27,200,091.53) compared to 'For' votes (34,062,064.00), indicating a notable level of shareholder dissent, although he was still elected.

Future Outlook

The elected Class I directors are set to serve until the Company's 2028 Annual Meeting of Stockholders.

Industry Context

This 8-K filing details the routine outcomes of an annual stockholder meeting, a standard corporate governance event for publicly traded companies. It reflects the company's compliance with SEC regulations regarding shareholder voting on key corporate matters such as director elections and auditor appointments.

Corporate Governance

Stakeholder Impact

• Shareholders exercised their voting rights on key corporate governance matters, including the election of directors and the ratification of the independent auditor.

Next Steps

• The elected Class I directors will serve until the Company's 2028 Annual Meeting of Stockholders.

Key Dates

Recommendation

Keywords

CG Oncology, CGON, SEC filing, 8-K, Annual Meeting, Stockholders, Director Election, Corporate Governance, Auditor Ratification, Ernst & Young, Nasdaq